RBC Capital Upgrades Dynavax Technologies (DVAX) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Dynavax (DVAX) Doubles Early on FDA Panel Backing
July 31, 2017 6:58 AM EDTDynavax (NASDAQ: DVAX) shares are trading up 105% in pre-open trade following FDA panel backing for HEPLISAV-B for hepatitis B.
... MoreJPMorgan Upgrades Dynavax Technologies (DVAX) to Overweight, Negatively Revises EPS Estimates
July 31, 2017 4:45 AM EDTJPMorgan upgraded Dynavax Technologies (NASDAQ: DVAX) from Neutral to Overweight with a price target of $27.00 (from $6.00).
Analyst Anupam Rama believes Heplisav has a high probability of a approval come August 10th PDUFA. Rama further comments about the under-appreciated SD-101 asset "we believe... More
